Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Recent News & Events
Preliminary Phase 2 PIK-201 data disappointed investors, triggering a 42% selloff; near-term focus shifts to FDA Phase 2 meeting minutes and Phase 3 plans.
NEGATIVENov 9, 2026
Clinical Trial Results
Phase 2 PIK-201 Topline Data Disappoints, Stock Plummets 42%
Faeth reported preliminary Phase 2 topline results for PIKTOR plus paclitaxel in advanced endometrial cancer, showing a 33% confirmed ORR and 7.4-month median PFS. Despite the company calling the data positive, investors focused on the modest response rate relative to expectations, driving the stock down over 40% on November 9. The selloff reflects concerns about competitive positioning versus newer treatments and uncertainty around Phase 3 advancement.
Management disclosed during the November 9 study update call that an FDA end-of-Phase 2 meeting occurred on November 3, 2026, with alignment generally reached on a potential go-forward plan. Meeting minutes are still awaited, and an explicit announcement on the Phase 3 registrational trial design is expected in the first half of 2027. Near-term, any update on FDA feedback could influence sentiment, though the timeline suggests limited immediate catalysts.
Faeth reported Q3 2026 financial results on November 3, 2026, highlighting a strengthened cash position of $174.8 million as of September 30, 2026, compared to $21.2 million at year-end 2025. The company also noted FDA Fast Track designation for PIKTOR and expected Phase 2 topline results by year-end. The strong cash runway reduces near-term financing risk but is largely overshadowed by the subsequent clinical data disappointment.